WARRIORNCT03417388
Women's IschemiA TRial to Reduce Events In Non-ObstRuctive CAD
At risk: Primary completion moved at least 8 months later.
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 49 versions: 42 with changes below, 7 re-verified with no change. See every version on ClinicalTrials.gov ↗
- Notable Primary completion pushed from May 31, 2024 to Feb 15, 2025
Notable Eligibility criteria expanded, about 15 words Show 6 more changesShow less
- Primary completion date changed from estimate of Sep 14, 2026 to May 31, 2024
- Study completion pushed from Sep 14, 2026 to Apr 16, 2027
- Secondary endpoints: details revised at 4 of 12 entries
- Study description revised
- Site details revised at 1 of 81 sites
- Publications: details revised at 4 of 4 entries
- Notable Sponsor changed: University of Florida to Cedars-Sinai Medical Center
- Site details revised at 1 of 81 sites
- Collaborators: 1 to 2
- Notable Primary and study completion dates pushed to Sep 14, 2026
- Trial status: Completed to Active, Not Recruiting
- Minor Trial status: Active, Not Recruiting to Completedv45
Show 36 earlier versionsHide 36 earlier versions
Notable Primary endpoints: 5 to 1v44 Show 4 more changesShow less
- Primary completion date changed from estimate of Feb 28, 2025 to Jan 3, 2025
- Study completion date: Sep 30, 2025 to Sep 14, 2025
- Interventions: ACE-I (lisinopril) or ARB (losartan) (Drug), Aspirin (Drug), High dose potent statin (Drug), Lifestyle Counseling (Behavioral), Quality of… to ACE-I (lisinopril) or ARB (losartan) (Drug), Aspirin 81 enteric coated tablet daily (Drug), High dose potent statin (Drug), Lifestyle…
- Secondary endpoints expanded, about 69 words
- Minor Primary completion date: Sep 30, 2024 to Feb 28, 2025
- Study completion date: Dec 30, 2024 to Sep 30, 2025
Notable Primary completion date: Sep 30, 2023 to Sep 30, 2024v41 Show 4 more changesShow less
- Trial status: Recruiting to Active, Not Recruiting
- Enrollment target: estimated 4422 to confirmed 2476
- Study sites: 83 to 81
- Study completion date: Dec 30, 2023 to Dec 30, 2024
- Minor Study sites: 84 to 83v40
- Minor Study sites: 68 to 84v39
- Notable Primary completion date: Dec 30, 2021 to Sep 30, 2023
- Study completion date: Dec 30, 2022 to Dec 30, 2023
- Study description revised
- Minor Study sites: 66 to 68v37
- Minor Study sites: 53 to 66v36
- Notable Eligibility criteria expanded, about 5 words
- Study sites: 49 to 53
- Minor Study sites: 46 to 49v34
- Minor Study sites: 45 to 46v33
- Minor Site details revised at 2 of 45 sitesv32
- Minor Study sites: 44 to 45v31
- Minor Study sites: 41 to 44v30
- Minor Study sites: 30 to 41v29
- Notable Eligibility criteria shortened, about 12 words
- Study sites: 29 to 30
- Minor Study sites: 28 to 29v27
- Notable Eligibility criteria revisedv25
- Minor Study sites: 27 to 28v24
- Notable Eligibility criteria revised
- Study sites: 25 to 27
- Notable Eligibility criteria expanded, about 52 wordsv21
- Minor Study sites revised (25)v20
- Minor Study sites: 24 to 25v18
- Notable Enrollment target: 550 to 4422
- Study sites: 23 to 24
- Notable Eligibility criteria expanded, about 1 wordv16
- Minor Study sites: 21 to 23v15
- Minor Study sites: 20 to 21v14
- Minor Study sites: 21 to 20
- Interventions: ACE-I (lisinopril) or ARB (losartan) (Drug), Aspirin (Drug), High dose potent statin (Drug), Lifestyle Counseling (Behavioral), PCSK9… to ACE-I (lisinopril) or ARB (losartan) (Drug), Aspirin (Drug), High dose potent statin (Drug), Lifestyle Counseling (Behavioral), Quality of…
- Study description shortened, about 19 words
- Minor Study sites: 20 to 21v12
- Minor Study sites: 17 to 20v10
- Minor Study sites: 15 to 17v9
- Minor Study sites: 12 to 15v8
- Notable Enrollment target: 4422 to 550
- Interventions: ACE-I (lisinopril) or ARB (losartan) (Drug), Aspirin (Drug), Evolocumab (Drug), High dose potent statin (Drug), Lifestyle Counseling… to ACE-I (lisinopril) or ARB (losartan) (Drug), Aspirin (Drug), High dose potent statin (Drug), Lifestyle Counseling (Behavioral), PCSK9…
- Minor Study sites: 11 to 12v4
Notable Trial status: Not Yet Recruiting to Recruitingv3 Show 4 more changesShow less
- Start date changed from estimate of Feb 2, 2018 to Feb 9, 2018
- Study description revised
- Site details revised at 11 of 11 sites
- Study title shortened, about 1 word
- Minor Study description expanded, about 1 wordv2
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Secondary (12)
Show 7 moreShow less
Arms and interventions
The IMT-assigned women will receive high dose potent statin, and moderate dose of an ACE-I (lisinopril) or ARB (losartan). Aspirin will also be recommended to IMT women without contraindications or bleeding risk. This group will also receive Lifestyle Counseling (PACE Assessment), Quality of Life questionnaires, and the same visit schedule and "face-time" with site staff to reduce bias.
The UC-assigned women will maintain standard of care. This group will also receive Lifestyle Counseling (PACE Assessment), Quality of Life questionnaires, and the same visit schedule and "face-time" with site staff to reduce bias.
Drugs: High dose potent statin, ACE-I (lisinopril) or ARB (losartan), Aspirin 81 enteric coated tablet daily
Behavioral: Lifestyle Counseling, Quality of Life Questionnaires
Sites
81 sites in 2 countries
United States 80, Puerto Rico 1